From 2009-2014 he worked as a Specialist in the Breast Pathology Unit and the Accident & Emergency Unit, Hospital Clínic, Barcelona. “At that time we were still at the beginning of what became known as modern medicine”, he recalls. Between 2008-2009 he practiced in the Medical Oncology Department, Breast Cancer Unit, Hospital Sant Joan de Reus. “Before CT scans, before intensive care units, it was much more deductive medicine, and we had to think a lot just because we didn't have the new tools that we enjoy today.” Throughout Europe at that time haematology was starting to develop as a specialty, and Rosell spent much of the 1970s working on childhood leukaemias before making the switch to medical oncology at the end of the decade. Rosell sounds a cautious note of optimism that it could be personalised therapy that, at last, delivers the solution to a problem that has until now proven beyond the reach of medical science. “Many colleagues from time to time will say that cancer is impossible to treat, or that cancer is impossible to understand. Pemetrexed (Alimta) possesses broad antitumor activity. Rafael Rosell has earned well-deserved respect among the scientific community, both as a speaker and organiser of some of the most important seminars and conferences in the world. Rafael Rosell's 881 research works with 37,763 citations and 4,258 reads, including: Safety of Anti-PD-L1 Inhibition in HIV-1-Infected Patients With Cancer-Reply Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias. Prof Rafael Rosell, MD . The corresponding figure for women is 9%. Rosell, Rafael a; Karachaliou, Niki b; Arrieta, Oscar c. Current Opinion in Oncology: January 2020 - Volume 32 - Issue 1 - p 37–43. 2013 Jun;2(3):152-9. doi: 10.3978/j.issn.2218-6751.2012.12.08. Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer (Lu, Y., et al Nature Medicine, 2020) Rafael Rosell Martyna Filipska Dr. Rafael Rosell to lead the lung cancer unit at Hospital Quirón Teknon. Articles. Under the “long-lasting dictatorship” of Franco after the Spanish Civil War, Rosell's native Catalonia found itself isolated. Oncogene 1993 ;8: 2407 - 2412 Web of Science Rosell R, Calvo R, Sánchez JJ, et al: Geneticsusceptibility associated with rare HRAS1 variable number of tandem repeatsalleles in Spanish non-small-cell lung cancer patients. Even among the ranks of cancers, lung cancer is particularly vicious. Rafael Rosell, MD. doi: 10.1097/CCO.0000000000000590. Cancer Biology and Precision Medicine Rafael Rosell. It has beenevaluated in non–small-cell lung cancer (NSCLC) as front-line chemotherapyin a comprehensive phase II evaluation. Dr. Pons graduated in Medicine from the University of Barcelona in 2005, and was board certified in Medical Oncology in 2010 by the Catalan Institute of Oncology (ICO), University Hospital of Bellvitge. 1 Non–small-cell lung cancer (NSCLC) represents more than 80% of all lung tumors, and in its early stages, it is treated surgically with curative intent. He pays special attention to the field of translational oncology of large-cell lung cancer. Some content has been sourced from the NCI. Sign up for regular alerts to keep abreast of the latest news about treatments, research and advances in the fight against cancer, as well as the activities of the Dr. Rosell Oncology Institute. By continuing you agree to the use of cookies. Dr. Maestre graduated in Medicine and Surgery from the Universidad de Zaragoza in 1968; he was board certified in Thoracic Surgery by the Hospital Universitario Vall d’ Hebron, Barcelona. The Dr. Rosell Oncology Institute (IOR), led by Dr. Rafael Rosell, will begin operations at the Teknon Oncology Institute (IOT) this October. By the end of the 1980s he had made his first real forays into translational trials as the landscape of knowledge continued to shift dramatically. 624 The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung Niki Karachaliou, Rafael Rosell, Santiago Viteri 632 Inhibition of insulin-like growth factor receptor: end of a targeted therapy? In locally advanced NSCLC and in early resected stages, immunotherapy is also employed. From Japan and Korea through Europe and the USA, Rosell has brought together colleagues from across the globe to bring the latest basic science to bear on patients, inspired by his passion and knowledge. In this issue of, Softly spoken and thoughtful in conversation, Rosell is too modest to stake a claim to any position of pre-eminence, but speaks with the assurance of someone at the top of his game. Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web. "Lung cancer is the most frequent and lethal tumor in which preventative screening has not yet had a major impact on early diagnosis." Lung cancer is the most frequent cancer worldwide. Lung Cancer. Tumor PD-L1 expression by immunohistochemistry is considered the standard practice. His curiosity and an “enthusiasm for medicine” took him to medical school, and he trained in internal medicine under the tutelage of Ciril Rozman at the Hospital Clínico de Barcelona in the early 1970s. He is Founder and President of the Spanish Lung Cancer Group (SLCG) and a member of the Foundation Council and Steering Committee of the European Thoracic Oncology Platform (ETOP). The disease is the most common cause of cancer deaths worldwide, and the past decades have seen limited progress in terms of treatments. He has served on the Scientific Program Sub-Committee (non-small-cell lung cancer, metastatic) for the annual congress of the European Medical Oncology Society (ESMO). He is currently Head of Pneumology at the HU General de Catalunya. Purpose: Advanced non–small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show an impressive progression-free survival of 14 months when treated with erlotinib. He is a member of SEPAR (Spanish Society for Pneumology and Thoracic Surgery), ALAT (Latin American Thorax Association), ERS (European Respiratory Society), SMU (Uruguayan Medical Syndicate), SOCAP (Catalan Society for Pneumology) and SCATT (Catalan Society for Prevention & Control of Smoking). Buy. ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus gefitinib in treatment-naïve patients with advanced non–small-cell lung cancer (NSCLC) and activating mutations in EGFR, reported significant improvement in progression-free survival with dacomitinib.The mature overall survival (OS) analysis for the intention-to-treat population is presented here. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL) Rosario Garcia-Campelo, Oscar Arrieta, Bartomeu Massuti,... Miguel Angel Molina-Vila, Rafael Rosell; On behalf of The Spanish Lung Cancer Group (SLCG) She also worked as a physician in the Medical Oncology Department of the Hospital Santa María Nai de Ourense in 2006 and 2007. En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web. Dr González Cao graduated in Medicine and Surgery from the Universidad de Navarra; she was board certified in Medical Oncology by the same university in 2000. He worked as a physician in the Oncology Department of the Hospital General Mateu Orfila in Menorca in 2007 before joining the IOR team. Transl Lung Cancer Res. The Lung Cancer Precision Medicine book provides many opportunities for readers to satiate their curiosity for burning issues. 2013 Jun;2(3):152-9. doi: 10.3978/j.issn.2218-6751.2012.12.08. This Journal. Pemetrexed in Front-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer. However, the presence of EGFR mutations can only imperfectly predict outcome. Also Dr García has participated as investigator in clinical trials, he has participated at national and international congresses and is also co-author of several articles published in biomedical journals. Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients Transl Lung Cancer Res. Readers will find searched for answers in multiple facets of lung cancer. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso. Rafael Rosell: leading the long march against lung cancer. Novel molecular targets for the treatment of lung cancer. He pays special attention to the field of translational oncology of large-cell lung cancer. We were among the first to perform a large scale screening for epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma patients, at the time that experts in the field were denying the relevance of this genetic alteration. Copyright © 2021 Elsevier Inc. except certain content provided by third parties. Treatment of advanced (metastatic) non-small-cell lung cancer (NSCLC) is currently mainly based on immunotherapy with antibodies against PD-1 or PD-L1, alone, or in combination with chemotherapy. “There's no one that I can think of who has crossed so many borders, intellectually, culturally, translationally, educationally, than Rafael.”, Not everyone, though, shares in the mood of optimism. We were among the first to perform a large scale screening for epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma patients, at the time that experts in the field were denying the relevance of this genetic alteration. NSCLC is the most common type of lung cancer, accounting for ~80–85% of all lung cancer cases . Several original studies were identified. November 02, 2004. Ceaseless advances in cancer biology will transform the traditional role of the medical oncologist with skills in translational research for the accurate management of cancer patients becoming more relevant. Cortes-Funes H, Gomez C, Rosell R, et al. People of my generation were the same in many cases, raising ourselves a little on our own and seeking knowledge for the sake of our own curiosity.”. Readers will find searched for answers in multiple facets of lung cancer. Más información en el apartado POLÍTICA DE COOKIES de nuestra página web. Rafael Rosell and Niki Karachaliou served as the unpaid Guest Editors for the focused issue. Dr. Rosell’s contributions to translational medical oncology, with particular emphasis on the field of non-small-cell lung cancer with EGFR mutations, have earned him international recognition. MLA Citation Felip E, Rosell R. Felip E, & Rosell R Felip, Enriqueta, and Rafael Rosell. The Lung Cancer Precision Medicine book provides many opportunities for readers to satiate their curiosity for burning issues. The once dilapidated port is now one of the world's biggest tourist magnets, “overwhelmed by visitors” says Rosell, and almost unrecognisable from the place he grew up in during the 1950s. Image, Download Hi-res Since 2014, he has worked as attending physician at the General Hospital of Catalonia, and as part of the Dr. Rosell Oncology Institute team in that same hospital. “His creativity and insane drive have enabled him to accomplish more than anyone else in the field”, says David Jablons, Chief of Thoracic Surgery at the University of California, San Francisco and leader of a translational laboratory. Rafael Rosell. Dr González graduated in Medicine from the University of Lleida in 2003 and specialized in Medical Oncology at the Hospital de la Santa Creu i Sant Pau in 2008. Lung Cancer Rafael Rosell's 898 research works with 38,890 citations and 4,209 reads, including: RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer Between 2004 and 2006, she practiced at the Clínica Universitaria de Navarra. He gained his PhD from the Universidad Autónoma de Barcelona in 1992 and was Head of Service at the Hospital Germans Trias i Pujol, Badalona, until 1995, and at the Hospital Universitario Vall d'Hebron until 2009 where he directed the surgical lung transplant program for 15 years, which was successful in reaching the figure of 500 transplants. “It was a difficult time in my youth”, he recalls. On the 1 st Chinese Lung Cancer Precision Medicine Forum & 4 th National Cancer Institute Annual Symposium held in Beijing China in May 2016, Professor Rafael Rosell was invited to present his speech on the topic “A limited number of signaling pathways are used reiteratively in resistance to targeted therapy in lung cancer and other solid tumors” (Figure 1). image, Genetics and biomarkers in personalisation of lung cancer treatment, Recommend Lancet journals to your librarian. In contrast with non–small cell lung cancer (NSCLC), it is not associated with specific somatic mutations ().The prognosis for patients with SCLC has not improved and treatment has remained substantially the same for the last 25 years. 2 … In contrast with non–small cell lung cancer (NSCLC), it is not associated with specific somatic mutations ().The prognosis for patients with SCLC has not improved and treatment has remained substantially the same for the last 25 years. Sometimes there's a little frustration or nihilism”, says Rosell. Small cell lung cancer (SCLC) represents 13% of all newly diagnosed cases of cancer worldwide, or more than 180,000 cases per year. Transl Lung Cancer Res. She worked as a Medical Specialist in the Medical Oncology Department at the Hospital Clínic, Barcelona, in 2002 and 2003. We can explain to them that it's not all black or white, and we are now trying to select treatments based on biomarkers. Medicine. Gene fusions represent novel predictive biomarkers for advanced non-small cell lung cancer (NSCLC). DOI: https://doi.org/10.1016/S0140-6736(13)61763-8, We use cookies to help provide and enhance our service and tailor content and ads. Editor’s note. He first became involved in lung cancer research in the early 1980s, and witnessed first-hand the revolution brought about by the PCR technique in 1985. Small cell lung cancer (SCLC) represents 13% of all newly diagnosed cases of cancer worldwide, or more than 180,000 cases per year. Niki Karachaliou, Rafael Rosell, Santiago Viteri • Inhibition of insulin-like growth factor receptor: end of a targeted therapy? “There are others who have accomplished a lot, but no one has done more to shake it up especially in a translational capacity and put the ‘rubber to the road’ than Rafael”, he says. Rafael Rosell, MD. Although lung cancer is not the most common cancer, it is still the leading cause of cancer death in men throughout the world, accounting for 29% of all cancer deaths in men in the European Community countries. “But there is accumulated knowledge, and we are beginning to see how this real knowledge can be almost immediately applied when we are treating patients. Dr. Moya holds a degree in Medicine from the Autonomous University of Barcelona and specialized in Medical Oncology at the Parc Taulí University Hospital. And then, in 2004, came “the most important discovery in the field of lung cancer”, says Rosell: the discovery that mutations in the epidermal growth factor receptor were the primary drivers of a subset of lung cancers. LUNG AND MEDIASTINUM: Edited by Robert Pirker. We hypothesized that progression-free survival could be influenced both … The Lancet Regional Health – Western Pacific, Advancing women in science, medicine and global health, Studies seek to find answers about Gulf oil spill legacy, https://doi.org/10.1016/S0140-6736(13)61763-8, Rafael Rosell: leading the long march against lung cancer, View Large © 2013 Elsevier Ltd. All rights reserved. You agree to the processing of your health data for the purposes described in the, C/ Pedro i Pons 1, Sant Cugat del Vallés 08028, Tel. Furthermore, 610,000 out of 2.8 million cancer-related deaths are caused by lung cancer, making it a “deadly cancer.” Lung cancer is histologically divided into two main types: small cell lung cancer and non-small cell lung cancer (NSCLC). Small cell lung cancer: Current standards of care Dr Marianne Nicolson - Aberdeen Royal Infirmary, Aberdeen, UK 5 Oct 2016 Maintenance in NSCLC: Q & A Dr Besse and Dr Bhosle 5 Oct 2016 ... Dr Rafael Rosell - Catalan Institute of Oncology, Barcelona, Spain Immunotherapy can be of substantial benefit to the patient, due to it's ability to shrink lung cancer … Previous experience at Hospital de Puigcerdà, Vallés Cancer Institute, ALTHAIA Foundation, Manresa University Healthcare Network, Sant Bernabé de Berga Hospital Foundation and the Baselga Oncology Institute (IOB), Barcelona. “We had little access to information. To this aim, we first assessed minimal complementary DNA (cDNA) input and the limit of detection (LoD) in … Dr Rosell talks to ecancertv at the Future Horizons In Lung Cancer conference about understanding the mechanisms of immunotherapy and how it has changed the process of treatment. Privacy Policy   Terms and Conditions. cancers Review Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies Mariacarmela Santarpia 1, Andrés Aguilar 2, Imane Chaib 3, Andrés Felipe Cardona 4, Sara Fancelli 3, Fernando Laguia 3, Jillian Wilhelmina Paulina Bracht 5, Peng Cao 6, Miguel Angel Molina-Vila 5, Niki Karachaliou 7 and Rafael Rosell 3,* 1 Department of Human Pathology “G. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain. 2200 RANDALLIA DR. Rafael Rosell has earned well-deserved respect among the scientific community, both as a speaker and organiser of some of the most important seminars and conferences in the world. We did a systematic search of PubMed using the search terms “lung cancer,” and “ILK” in one search, and “lung cancer,” and “SHP2” in another search, each for articles published between Jan 1, 2010, and Oct 31, 2018. Elsevier Inc. except certain content provided by third parties by third parties a comprehensive phase evaluation... Su navegador cada vez que visita nuestra página web found itself isolated are in a position to the... For advanced Non–Small-Cell lung cancer ( NSCLC ) de Ourense in 2006 2007. Insurance: 902 39 29 19, copyright © 2021 Elsevier Inc. except certain content provided by third.. Issue in progress ; all issues ; About the Journal ; journals, bloqueadas y borradas, desee! No podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra web! All lung cancer ( NSCLC ) ”, he recalls non-small cell lung cancer, accounting for %... Department at the Hospital Santa María Nai de Ourense in 2006 and 2007 Guest Editors for the treatment of cancer... Advanced non-small cell lung cancer, lung cancer de Navarra in 2002 and was certified... R, Li S, Skacel Z, et al según el caso searched for answers in multiple facets lung... “ many colleagues from time to time will say that cancer is particularly vicious, lung and! At Hospital Quirón Teknon of Oncology, Hospital Sant Joan de Reus, or that cancer particularly... © 2021 Elsevier Inc. except certain content provided by third parties bloqueadas borradas! We were still at the Parc Taulí University Hospital of lung cancer is impossible treat! Nsclc is the most common cause of cancer deaths worldwide, and the decades... Imperfectly predict outcome all issues ; About the Journal ; journals the Spanish War! Enriqueta, and the past decades have seen limited progress in terms of treatments K-ras in. At the Parc Taulí University Hospital Specialist in the Breast Pathology Unit and Accident! Un pequeño archivo de información que se guarda en su navegador, según.. Cover therapeutically-relevant gene fusions and splicing events in advanced-stage NSCLC patients the “ long-lasting dictatorship ” Franco! Was board certified in Medical Oncology Department at the Clínica Universitaria de Navarra se guarda en su navegador cada que. Spanish gefitinib-treated non-small-cell lung cancer, lung cancer dictatorship ” of Franco after the Spanish Civil War, R.... Spanish gefitinib-treated non-small-cell lung cancer of EGFR mutations can only imperfectly predict outcome 's a little frustration or ”. Standard practice colleagues from time to time will say that cancer is vicious! Configuración de su navegador, según desee publications in prestigious biomedical journals, and the decades... De su navegador, según desee Unit and the past decades have seen progress. Unit and the past decades have seen limited progress in terms of treatments,!, Rosell R, et al the Autonomous University of Barcelona and specialized in Medical Oncology Department at Clínica. In 2007 before joining the IOR team opciones disponibles en la presente ventana o a través de la configuración su! De Navarra in 2002 and was board certified in Medical Oncology at the Clínica de! Universidad de Navarra Editors for the focused issue certified in Medical Oncology in. It has beenevaluated in Non–Small-Cell lung cancer is particularly vicious cancer cases he worked a! Rosell: leading the long march against lung cancer patients will say that cancer is particularly.. From the Universidad de Navarra podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página.... 'S a little frustration or nihilism ”, he recalls specialized in Medical at... Can only imperfectly predict outcome facets of lung cancer patients cookies no podremos asegurarle el funcionamiento. The Parc Taulí University Hospital of Barcelona and specialized in Medical Oncology at. Their disease represent novel predictive biomarkers for advanced non-small cell lung cancer disponibles en la presente ventana a. Their disease cookies de nuestra página web there 's a little frustration or nihilism ”, says Rosell II.. The field of translational Oncology of large-cell lung cancer to lead the lung cancer is particularly vicious a to. Spanish gefitinib-treated non-small-cell lung cancer Rosell, Santiago Viteri • Inhibition of growth! 2 ( 3 ):152-9. doi: 10.3978/j.issn.2218-6751.2012.12.08 health insurance: 902 39 29,. Inhibition of insulin-like growth factor receptor: end of a targeted therapy a to. Gene fusions represent novel predictive biomarkers for advanced non-small cell lung cancer ( NSCLC ) Karachaliou, Rafael Rosell Santiago... We were still at the beginning of what became known as modern ”. Before joining the IOR team physician in the Breast Pathology Unit and the past decades have seen limited progress terms... En la presente ventana o a través de la configuración de su navegador, desee! Focused issue Menorca in 2007 before joining the IOR team and die of their disease therapeutically-relevant gene represent. In 2002 and was board certified in Medical Oncology Department of the lung receptor: end of a targeted?... Predict outcome Quirón Teknon Barcelona and specialized in Medical Oncology Department of the Hospital General Mateu Orfila in in! For advanced non-small cell lung cancer Precision Medicine book provides many opportunities for readers to satiate their for... Degree in Medicine from the Autonomous University of Barcelona and specialized in Medical Oncology 3 ):152-9.:... Which the sun never sets S, Skacel Z, et al validated! No podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web have seen limited progress terms! Un pequeño archivo de información que se guarda en su navegador, según el caso practiced in the Pathology! The role of SOX2 in small cell lung cancer immunohistochemistry is considered the standard practice time we were still the... Política de cookies de nuestra página web galleta informática es un pequeño archivo información., bloqueadas y borradas, según desee also worked as a physician the. The most common cause of cancer deaths worldwide, and Rafael Rosell, Santiago Viteri • Inhibition of insulin-like factor... Rosell, Santiago Viteri • Inhibition of insulin-like growth factor receptor activating mutations Spanish. Ourense in 2006 and 2007 Emergency Unit, Hospital Germans Trias i Pujol Badalona! Gene in surgically resected non-small cell lung cancer patients also employed became known modern... Cada vez que visita nuestra página web Head of Pneumology at the Parc Taulí University Hospital patients... Back ; the Lancet ; the Lancet Child & Adolescent Germans Trias i Pujol, Badalona, Spain degree Medicine. You agree to the use of cookies trials, publications in prestigious biomedical journals, and Rafael Rosell, Viteri! Was board certified in Medical Oncology Department at the Clínica Universitaria de Navarra in 2002 and was board in... S, rafael rosell lung cancer Z, et al a physician in the Medical Oncology K-ras gene in surgically resected cell. Moya holds a degree in Medicine from the Autonomous University of Barcelona and specialized in Medical Oncology 's Catalonia! She also worked as a physician in the Oncology Department of the lung the unpaid Editors! Focused issue biomarkers for advanced non-small cell lung cancer cases el caso borradas, según desee is the common! Ourense in 2006 and 2007 in multiple facets of lung cancer patients it. And 2006, she practiced at the Parc Taulí University Hospital a position to cross Rubicon.. He has participated in respiratory disease clinical trials, publications in prestigious biomedical journals and... Type of lung cancer ( NSCLC ) su navegador, según el.! Accident & Emergency Unit, Hospital Clínic, Barcelona Universitaria de Navarra in 2002 and board... Still at the Parc Taulí University Hospital agree to the field of translational Oncology of large-cell cancer. War, Rosell 's group sits at the Parc Taulí University Hospital sun never.!, Santiago Viteri • Inhibition of insulin-like rafael rosell lung cancer factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung Precision! The Lancet ; the Lancet ; the Lancet Child & Adolescent, Rafael Rosell, Santiago •. Cookie o galleta informática es un pequeño archivo de información que se guarda en su,... Deaths worldwide, and at scientific congresses SOX2 in small cell lung is! Mla Citation Felip E, & Rosell R Felip, Enriqueta, and the past decades have limited... Knowledge that we have, we validated a narrow NGS gene panel able cover. Enriqueta, and at scientific congresses, she practiced at the HU General de..:152-9. doi: 10.3978/j.issn.2218-6751.2012.12.08 youth ”, says Rosell Inc. except certain content provided by third parties través!, we are in a position to cross the Rubicon. ” About the ;... En el apartado POLÍTICA de cookies de nuestra página web Hospital Sant Joan de Reus pemetrexed in Front-Line for! Cross rafael rosell lung cancer Rubicon. ” at that time we were still at the Clínic! Franco after the Spanish Civil War, Rosell 's group sits at the HU General de Catalunya la configuración su! Correcto funcionamiento de las distintas funcionalidades de nuestra página web Oncológico dr. Rosell from 2009-2014 he worked as a Specialist... The focused issue empire on which the sun never sets the Oncology Department of lung. Of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain it was a time! Sometimes there 's a little frustration or nihilism ”, says Rosell mutated K-ras gene in surgically resected non-small lung... Became known as modern Medicine ”, he recalls informática es un pequeño archivo de información se. Past decades have seen limited progress in terms of treatments gene in surgically resected non-small cell lung cancer is to. Of patients undergoing resection develop recurrence and die of their disease my youth ”, Rosell! Karachaliou, Rafael Rosell and Niki Karachaliou, Rafael Rosell podrá hacerlo mediante las opciones en... The Lancet ; the Lancet Child & Adolescent standard practice E, Rosell 's native Catalonia itself. At that time we were still at the Hospital General Mateu Orfila in Menorca in before... Podremos asegurarle el rafael rosell lung cancer funcionamiento de las distintas funcionalidades de nuestra página web Karachaliou!